Oncology
Myelofibrosis
Conference Reporter® Podcast: The Mechanism of Action of JAK Inhibitors and Novel Mechanisms of Action in Myelofibrosis
JAK inhibitors work by blocking the overactive signaling pathways that drive inflammation and cell growth in myelofibrosis, while novel agents target independent biological pathways to overcome drug resistance or treat fibrosis directly. As discussed in today’s podcast, data presented at the recent 2026 ASCO Annual Meeting indicate that this nuanced understanding of drug mechanism of action assists clinicians in selecting the most appropriate JAK inhibitor for patients based on specific clinical features.
Following these presentations, featured expert Aaron T. Gerds, MD, MS, was interviewed by Conference Reporter Associate Editor-in-Chief Rick Davis, MS, RPh. Clinical perspectives from Dr Gerds on these findings are presented here.
Gerds AT, Fleischman AG, Mascarenhas J, et al. Expert perspectives in the management of myelofibrosis (MF): a survey of 20 US-based specialists [abstract e18590] [session: Publication only: hematologic malignancies—leukemia, myelodysplastic syndromes, and allotransplant]. Abstract presented at: 2026 American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2026; Chicago, IL. Accessed July 15, 2026. https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.e18590
Mascarenhas J, Ali H, Al-Ali HK, et al. Selinexor plus ruxolitinib in JAK inhibitor-naïve myelofibrosis: phase 3 SENTRY trial [abstract LBA6500] [session: Hematologic malignancies—leukemia, myelodysplastic syndromes, and allotransplant]. Abstract presented at: 2026 American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2026; Chicago, IL.
Rinaldi CR, Finch H, Fahy S, Archer S. A phase 2 study to assess the safety and efficacy of bomedemstat (IMG-7289) in combination with momelotinib in patients with myelofibrosis [abstract TPS6605] [session: Hematologic malignancies—leukemia, myelodysplastic syndromes, and allotransplant]. Poster presented at: 2026 American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2026; Chicago, IL.
This information is brought to you by Engage Health Media and is not sponsored, endorsed, or accredited by the American Society of Clinical Oncology.
